School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.
Medicine (Baltimore). 2022 Sep 9;101(36):e30542. doi: 10.1097/MD.0000000000030542.
This retrospective analysis aimed to compare the risk of venous thromboembolism (VTE) between patients with diabetes mellitus who received hydrophilic statin treatment to those who receive lipophilic statin. There were 6639 patients receiving hydrophilic statin therapy and 10,854 patients receiving lipophilic statin therapy in the study. The hazard ratios and 95% confidence intervals for VTE were estimated using univariate and multivariate Cox proportional hazards models when the study cohorts were compared. Among all patients, the incidence rate of VTE was 4.27 per 1000 person-years in the control cohort, 4.18 per 1000 person-years in the hydrophilic statin use cohort, and 3.91 per 1000 person-years in the lipophilic statin use cohort. After adjusting for age, sex, and comorbidities, the risk of VTE in the hydrophilic statin use cohort was 0.90 (0.72, 1.12) lower than that in the control cohort, the risk of VTE in the lipophilic statin use cohort was 0.87 (0.72, 1.05) lower than that in the control cohort, and the risk of VTE in the lipophilic statin use cohort was 0.97 (0.78, 1.21) lower than that in the hydrophilic statin use cohort. However, all were not statistically significant. Our result showed that there was no significant difference among the study cohorts regarding the outcome of VTE.
本回顾性分析旨在比较接受亲水他汀治疗和脂溶性他汀治疗的糖尿病患者发生静脉血栓栓塞（VTE）的风险。研究中共有 6639 例接受亲水他汀治疗的患者和 10854 例接受脂溶性他汀治疗的患者。当比较研究队列时，使用单变量和多变量 Cox 比例风险模型估计 VTE 的风险比和 95%置信区间。在所有患者中，对照组的 VTE 发生率为每 1000 人年 4.27 例，亲水他汀治疗组为每 1000 人年 4.18 例，脂溶性他汀治疗组为每 1000 人年 3.91 例。在调整年龄、性别和合并症后，亲水他汀治疗组的 VTE 风险比对照组低 0.90（0.72，1.12），脂溶性他汀治疗组的 VTE 风险比对照组低 0.87（0.72，1.05），而脂溶性他汀治疗组的 VTE 风险比亲水他汀治疗组低 0.97（0.78，1.21）。然而，所有这些差异均无统计学意义。我们的结果表明，研究队列在 VTE 结局方面没有显著差异。
